Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4917794 | 0.92 | LMNA (0.52) | ALDH1A1POLBGAAACKR3SMN1; SMN2 | |
| SCHEMBL4920802 | 0.91 | SMN1; SMN2 (0.51) | ALDH1A1POLBGAASMN1; SMN2LMNA | |
| SCHEMBL4917811 | 0.91 | PPARG (0.57) | ALDH1A1POLBGAAATMACKR3 | |
| SCHEMBL4922456 | 0.90 | ALDH1A1 (0.50) | ALDH1A1POLBGAAATMSMN1; SMN2 | |
| SCHEMBL4922789 | 0.89 | TSHR (0.60) | ACKR3SMN1; SMN2LMNACACNA1GTSHR | |
| SCHEMBL4917352 | 0.89 | SMN1; SMN2 (0.49) | ALDH1A1POLBGAASMN1; SMN2LMNA | |
| SCHEMBL4924772 | 0.88 | ACKR3 (0.53) | ALDH1A1GAAACKR3CACNA1GTSHR | |
| SCHEMBL4924133 | 0.84 | ALDH1A1 (0.61) | ALDH1A1POLBGAAATMACKR3 | |
| SCHEMBL4915799 | 0.84 | L3MBTL1 (0.50) | ACKR3SMN1; SMN2LMNATSHRMEN1 | |
| SCHEMBL5577516 | 0.83 | ALDH1A1 (0.66) | ALDH1A1POLBGAAATMACKR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080081824-A1 | Substituted piperidines as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080081824-A1 | Substituted piperidines as modulators of chemokine receptor activity | CCR1, CCR3, CCR2 | ALDH1A1 1255/4885POLB 2562/4885GAA 4442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.